Azacitidine (5-Azacytidine)

Name: Azacitidine (5-Azacytidine)
Brand: Selleck Chemicals
SKU: S1782
Rating: 5 (39 reviews)

For research use only.

Catalog No.S1782 Synonyms: 5-AzaC,Ladakamycin, AZA,5-Aza

39 publications

Azacitidine (5-Azacytidine) Chemical Structure

CAS No. 320-67-2

Azacitidine (5-Azacytidine, 5-AzaC, Ladakamycin, AZA, 5-Aza) is a nucleoside analogue of cytidine that specifically inhibits DNA methylation by trapping DNA methyltransferases. Azacitidine induces mitochondrial apoptosis and autophagy.

Selleck's Azacitidine (5-Azacytidine) has been cited by 39 publications

Cancer Cell, 2019, 35(2):333-335

PubMed: 30753831 ( click the link to review the publication )

Cancer Cell, 2018, 34(5):724-740.e4

PubMed: 30423294 ( click the link to review the publication )

Cell, 2017, S0092-8674(17)31382-X

PubMed: 29249359 ( click the link to review the publication )

Cancer Cell, 2017, 31(6):833-843

PubMed: 28552327 ( click the link to review the publication )

PLoS Pathog, 2020, 16;16(3):e1008341

PubMed: 32176725 ( click the link to review the publication )

Neoplasia, 2020, 22(3):142-153

PubMed: 32062068 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(9):5260-5273

PubMed: 32227582 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

G3 (Bethesda), 2020, 4;10(5):1585-1597

PubMed: 32265286 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Technol Cancer Res Treat, 2020,

PubMed: 32715976 ( click the link to review the publication )

Blood Adv, 2020, 4(18):4393-4405

PubMed: 32926125 ( click the link to review the publication )

Genes Chromosomes Cancer, 2020, 10.1002/gcc.22884

PubMed: 32614991 ( click the link to review the publication )

Clin Transl Oncol, 2020, 10.1007/s12094-020-02464-x

PubMed: 32737836 ( click the link to review the publication )

J Biochem Mol Toxicol, 2020, e22621

PubMed: 32894642 ( click the link to review the publication )

Stem Cell Reports, 2020, 15(2):408-423

PubMed: 32735821 ( click the link to review the publication )

J Clin Invest, 2019, 10.1172/JCI128571

PubMed: 31437130 ( click the link to review the publication )

Cancer Immunol Res, 2019, 7(2):230-243

PubMed: 30563830 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):277

PubMed: 31653272 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):900-908

PubMed: 30824609 ( click the link to review the publication )

Cell Commun Signal, 2019, 17(1):4

PubMed: 30642362 ( click the link to review the publication )

Environ Toxicol, 2019, 10.1002/tox.22873

PubMed: 31724259 ( click the link to review the publication )

Commun Biol, 2019, 2:272

PubMed: 31372511 ( click the link to review the publication )

Blood, 2018, 131(14):1576-1586

PubMed: 29437595 ( click the link to review the publication )
Elife, 2018, 7

PubMed: 30412053 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):62

PubMed: 29728108 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 5;37(1):305

PubMed: 30518424 ( click the link to review the publication )

PLoS Pathog, 2018, 14(6):e1007061

PubMed: 29879225 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2091-2099

PubMed: 30045927 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(5)E1414

PubMed: 29747401 ( click the link to review the publication )

Int J Mol Sci, 2018, 20(1)

PubMed: 30577584 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(9):1243-1254

PubMed: 28522693 ( click the link to review the publication )

Leuk Res, 2017, 58:91-97

PubMed: 28505595 ( click the link to review the publication )

Leuk Res, 2017, 56:36-43

PubMed: 28171800 ( click the link to review the publication )

FEBS J, 2016, 283(20):3739-3754

PubMed: 27573079 ( click the link to review the publication )

Oncotarget, 2016, 8(60):100975-100988

PubMed: 29254139 ( click the link to review the publication )

Sci Transl Med, 2015, 7(290):290ra89

PubMed: 26041706 ( click the link to review the publication )

Epigenetics, 2015, 10.1080/15592294.2015.1039216

PubMed: 25923331 ( click the link to review the publication )

Oncotarget, 2015, 6(19):17698-712

PubMed: 25989842 ( click the link to review the publication )

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description

Targets

DNA methyltransferase ^[1]
(Cell-free assay)

In vitro

Azacitidine is widely used to demonstrate the correlation between loss of methylation in specifc gene regions and activation of the associated genes. After incorporation into DNA, Azacitidine inhibits DNA methyltransferase noncompetitively, causing a block in cytosine methylation in newly replicated DNA but not in resting, nondividing cells. ^[1] Azacitidine induces differentiation of Friend Erythroleukemia Cell C3H10T1/2 with myotube formation. ^[2] Azacitidine can be activated to the nucleoside triphosphate and incorporate into both DNA and RNA, leading to inhibition of DNA, RNA and protein synthesis in normal eukaryotic cells and in cancer cell lines, which could finally leads to cell death. Azacitidine also inhibits the incorporation of purine metabolites into macromolecules. Azacitidine inhibits the L1210 cells growth with IC50 and of 0.019 μg/mL. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Raji	NVHCWnFtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{fodlAvOS13MDFOwG0>	MXSxNk04OiCq		M4KzN4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	NVHPbHlLOjZzM{OyOFY>
Jurkat	NUHEXFQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHHwOVgxNjFvNUCg{txO	MVGxNk04OiCq		M{\jR4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	MkT5NlYyOzN{NE[=
CA46	NYnPTWI4TnWwY4Tpc44hSXO\|YYm=	NFrueI4zOMLiwsXN	M1O2O\|Q5KGh?		NV\3Umh[cW6lcnXhd4V{yqCSVGDMNeKhdVKQQTDlfJBz\XO\|aX;u	NY[yVXpGOjZzM{OyOFY>
Raji	MoHHSpVv[3Srb36gRZN{[Xl?	NVq5NppnOTYEoNM1US=>	NHy4TVQ1QCCq		MUjpcoNz\WG\|ZYRCpHBVWExzwrDtVm5CKGW6cILld5Nqd25?	M{HPd\|I3OTN\|MkS2
Jurkat	NVHXXYZCTnWwY4Tpc44hSXO\|YYm=	M2XhTVMvPcLiwsXN	M3zpR\|Q5KGh?		M{\IeYlv[3KnYYPld:KhWFSSTEJCpI1TVkFiZYjwdoV{e2mxbh?=	M2rHd\|I3OTN\|MkS2
MDA-MB-231	Mlv5SpVv[3Srb36gRZN{[Xl?	MXexM\|IvPS93IN88US=>	MnyzOFghcA>?		NGnGZZBl\WO{ZXHz[ZMhfGinIGDUVG4yOiCneIDy[ZN{cW:wIHH0JJRp\SClb37j[ZJvfHKjdHnvckBw\iB3wrFOwG0hPDkEoHi=	M3jjXVI2QDF5MkK5
MDA-MB-231	MYjGeY5kfGmxbjDBd5NigQ>?	MV6xM\|IvPS93IN88US=>	Mk\UOFghcA>?		NH;kUodqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjDFMYNi\GincnnuJI1TVkFiYYSgeIhmKGOxbnPldo51emG2aX;uJI9nKDJwNdMg{txO\m:{IES4xsBp	MVGyOVgyPzJ{OR?=
MDA-MB-231	MYHGeY5kfGmxbjDBd5NigQ>?	NUDTSZppOS9{LkWvOUDPxE1?	NVm1XI9WOjRxNEigbC=>		NIj1NoFqdmS3Y3XzJEB{cWewaX\pZ4FvfCCSQWLQJINt\WG4YXflJIFnfGW{IES4JIg>	NVr6WpRjOjV6MUeyNlk>
MCF-7	MonISpVv[3Srb36gRZN{[Xl?	NUm0OIZ5OS9{LkWvOUDPxE1?	NIrYR3UzPC92ODDo		MWXpcoNz\WG\|ZYOgVGFTWCClbHXheoFo\cLi	MUSyOVgyPzJ{OR?=
MDA-MB-231	MXLGeY5kfGmxbjDBd5NigQ>?	MXGxM\|IvPS93IN88US=>	MmLLNlQwPDhiaB?=		MYjpcoNz\WG\|ZYOgeIhmKGW6cILld5Nqd25ib3[gcYlTVkFvMUK0JIF1KHSqZTDjc45k\XKwdILheIlwdiCxZjC1JO69VQ>?	NX:xd5NyOjV6MUeyNlk>
A498	NEDiOo9HfW6ldHnvckBCe3OjeR?=	MoT0NVAhyrWP	M{Ta[\|czKGh?		NIrMWmJqdmS3Y3XzJJRp\SCDRFHNWHMyQCCpZX7lJIV5eHKnc4Ppc44>	MWWyOVU3QTB6Nh?=
CaKI-2	NVTyUllNTnWwY4Tpc44hSXO\|YYm=	NWLFfpdSOTBiwsXN	M4qxdlczKGh?		NGfk[ZNqdmS3Y3XzJJRp\SCDRFHNWHMyQCCpZX7lJIV5eHKnc4Ppc44>	NYO3Z2pWOjV3NkmwPFY>
Ketr-3	NYTlTZFITnWwY4Tpc44hSXO\|YYm=	NHv3c2kyOCEEtV2=	M{XC[\|czKGh?		MnXPbY5lfWOnczD0bIUhSUSDTWTTNVgh\2WwZTDlfJBz\XO\|aX;u	M2TWSlI2PTZ7MEi2
A253	NWLqd49MTnWwY4Tpc44hSXO\|YYm=	MmLXNVAhyrWP	MYiwMVQh\A>?		NHrVVIdqdmO{ZXHz[ZMhfGinIH3SUmEh\XiycnXzd4lwdiCuZY\lcEBw\iC2aHWgUVNTyqCjZoTldkAzPCCq	NU\P[5lLOjV2OEW1N\|Y>
A253	MoDUSpVv[3Srb36gRZN{[Xl?	MXexNEDDvU1?	MmrVO\|IhcA>?		MlvSbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIITo[UBOO1JiaX6gZo91cCCvZX3idoFv\SCjbnSgZ5l1d3OxbHnjJJBz\XCjcnH0bY9vew>?	MWWyOVQ5PTV\|Nh?=
A253	NYnDbpVDTnWwY4Tpc44hSXO\|YYm=	NHHiNWoyOCEEtV2=	MYCwMVQh\A>?		NI\nc4Zz\WS3Y3XzJJRp\SB3LX3leIh6dGO7dH;zbY5mKGOxboTlcpQ>	NHnrNYozPTR6NUWzOi=>
PC3	MV\GeY5kfGmxbjDBd5NigQ>?	MVKwMlIh\|ryPwrC=	MXq0JIQ>		Mlf4bY5kemWjc3XzJJRp\SCpZX7lJIV5eHKnc4Ppc44hd2ZiSVfGRnA4NCCVRmLQNUBidmRiU1zDOmEyPSClb33ibY5m\CC5aYToJGdUUzF{Nh?=	NWfZdVA3OjV2N{ezOFA>
MCF7	MojESpVv[3Srb36gRZN{[Xl?	M{LkUFAvOyEQvF5CpC=>	NF3nc4g1KGR?		NET1fFlqdmO{ZXHz[ZMhfGinIHflcoUh\XiycnXzd4lwdiCxZjDJS2ZDWDduIGPGVnAyKGGwZDDTUGM3STF3IHPvcYJqdmWmIIfpeIghT1ONMUK2	Mn3KNlU1Pzd\|NEC=
PC3	NYTwTXVjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX2wMlIh\|ryPwrC=	NWDaRm9uPCCm		MWHk[YNz\WG\|ZYOgeIhmKGOnbHyg[5Jwf3SqIITvJFIxNjNnIHPvcYJqdmWmIIfpeIghT1ONMUK2	M3vLPFI2PDd5M{Sw
MCF7	NHfqUllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFj2VJUxNjNizszNxsA>	NEe3N4g1KGR?		M3PEc4Rm[3KnYYPld{B1cGViY3XscEBoem:5dHigNlQvQCViY3;tZolv\WRid3n0bEBIW0tzMk[=	NHrGZZczPTR5N{O0NC=>
BGC-823	MUXGeY5kfGmxbjDBd5NigQ>?	NYPyTYVKPcLizszN	M2rM[VczKGh?		MoPO[IVkemWjc3XzJJRp\SCSUlytN{Bxem:2ZXnuJIxmfmWuIIPp[45q\mOjboTsfS=>	NHzyTZozPTR5NUezNy=>
MKN28	NVvJPIROTnWwY4Tpc44hSXO\|YYm=	NVW4VFFjPcLizszN	NULDV2ZWPzJiaB?=		MX3k[YNz\WG\|ZYOgeIhmKFCUTD2zJJBzd3SnaX6gcIV3\Wxic3nncoln[2GwdHz5	NYi0codMOjV2N{W3N\|M>
SGC-7901	MnXKSpVv[3Srb36gRZN{[Xl?	MVe1xsDPxE1?	MVG3NkBp		NXGxXZNJ\GWlcnXhd4V{KHSqZTDQVmwuOyCycn;0[YlvKGyndnXsJJNq\26rZnPhcpRtgQ>?	M3LGd\|I2PDd3N{Oz
MKN45	M{PrR2Z2dmO2aX;uJGF{e2G7	NXPpXno4PcLizszN	NWPodIIzPzJiaB?=		NELUOJBl\WO{ZXHz[ZMhfGinIGDSUE0{KHC{b4TlbY4hdGW4ZXygd4lodmmoY3HueIx6	NXXnTIhzOjV2N{W3N\|M>
BGC-823	NX3RR3d[TnWwY4Tpc44hSXO\|YYm=	MkHMOeKh\|ryP	Mn;oO\|IhcA>?		Mn;S[IVkemWjc3XzJJRp\SCvUl7BJIV5eHKnc4Ppc44hd2ZiUGLMMVMhe2mpbnnmbYNidnSueR?=	NGTadVkzPTR5NUezNy=>
MKN28	NUDNWIdDTnWwY4Tpc44hSXO\|YYm=	NV[1XFA4PcLizszN	M1LQTVczKGh?		MmnY[IVkemWjc3XzJJRp\SCvUl7BJIV5eHKnc4Ppc44hd2ZiUGLMMVMhe2mpbnnmbYNidnSueR?=	Ml7aNlU1PzV5M{O=
SGC-7901	M2T6fGZ2dmO2aX;uJGF{e2G7	NYHTZ25XPcLizszN	MU[3NkBp		MYnk[YNz\WG\|ZYOgeIhmKG2UTlGg[ZhxemW\|c3nvckBw\iCSUlytN{B{cWewaX\pZ4FvfGy7	MUKyOVQ4PTd\|Mx?=
MKN45	M3HVUWZ2dmO2aX;uJGF{e2G7	NGXTcIo2yqEQvF2=	Mnj2O\|IhcA>?		MV7k[YNz\WG\|ZYOgeIhmKG2UTlGg[ZhxemW\|c3nvckBw\iCSUlytN{B{cWewaX\pZ4FvfGy7	MlXZNlU1PzV5M{O=
HREC	M1js[GZ2dmO2aX;uJGF{e2G7	M2T4T\|UwOTEEoN88US=>	MUe0PEBp		NVn1e5hOcW6mdXPld{BRTUSIIHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NHLTNIkzPTN3Mke0Oy=>
HRPE	M4SxVWZ2dmO2aX;uJGF{e2G7	MYe1M\|ExyqEQvF2=	NYnvNnpmPDhiaB?=		MnSzbY5lfWOnczDQSWRHKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NGruc4wzPTN3Mke0Oy=>
HREC	NYLIXoE2TnWwY4Tpc44hSXO\|YYm=	NIDpOm82NzFywrFOwG0>	MWm0PEBp		Mlnz[I94di2{ZXf1cIF1\XNib3[gWmVITixiSVPBUU0yKCiwb4SgdJJwfGWrbjDs[ZZmdCCrbjDIVnBGKGOnbHzzLUwhUUxvMd8yJIRwe2VvZHXw[Y5l\W62bIm=	NUe4R4hiOjV\|NUK3OFc>
HRPE	MlrjSpVv[3Srb36gRZN{[Xl?	NWrWcGM6PS9zMNMg{txO	NYLtOoFYPDhiaB?=		MVnkc5dvNXKnZ4XsZZRmeyCxZjDWSWdHNCCLTD2x{tItKGGwZDDNUXAzKGSxc3Wt[IVx\W6mZX70cJk>	M3ywOlI2OzV{N{S3
MSCs	NIjrPG9HfW6ldHnvckBCe3OjeR?=	M{XmN\|ExKM7:TR?=	NIq1UG8zPCCq		MmnJdJJwdW:2ZYOgeIhmKGOxbX3peI1mdnRib3[gUXNEeyC2bzDtfY9k[XKmaXHsJIRq\m[ncnXueIlifGmxbh?=	NX7vdYdUOjV\|NUGzPVU>
HL-60	M2DnNWZ2dmO2aX;uJGF{e2G7	M3WzOVUh\|ryP	M4\oVFczKGh?	MmHaSG1UVw>?	MlGxd4lodmmoaXPhcpRtgSC3cILl[5Vt[XSnczDaUmY{QDJiZYjwdoV{e2mxbh?=	M{HyPVI2OzF7MES5
MV4-11	MYPGeY5kfGmxbjDBd5NigQ>?	NYfrSJA4PSEQvF2=	NEjCbYo4OiCq	NXrtVFhJTE2VTx?=	NYnr[XRLe2mpbnnmbYNidnSueTD1dJJm\3WuYYTld{BbVkZ\|OEKg[ZhxemW\|c3nvci=>	M2XNNlI2OzF7MES5
A2780	MXrGeY5kfGmxbjDBd5NigQ>?	Mo\1OUDDvU4EoB?=	MoTxO{Bl		NX7lZohVcW6lcnXhd4V{KESQQTDt[ZRpgWyjdHnvckBt\X[nbB?=	NFvI[2ozPTJ7OU[5OC=>
CP70	NUnORXRwTnWwY4Tpc44hSXO\|YYm=	NFLJXng2KML3TdMg	NFrqeGE4KGR?		NH\XUJRqdmO{ZXHz[ZMhTE6DIH3leIh6dGG2aX;uJIxmfmWu	MoPINlUzQTl4OUS=
A2780	MnrKSpVv[3Srb36gRZN{[Xl?	Mn\wOUDDvU4EoB?=	NWe1d5R4PyCm		MX33[YFs\W6\|IITo[UBt\X[nbDDv[kBu\XSqeXzheIlwdg>?	NYezXWNROjV{OUm2PVQ>
CP70	NWH0TW9OTnWwY4Tpc44hSXO\|YYm=	MYO1JOK2VcLi	NGjUZ\|c4KGR?		NI[3XW14\WGtZX7zJJRp\SCuZY\lcEBw\iCvZYTofYxifGmxbh?=	M1L4V\|I2Ojl7Nkm0
OCM3	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVH2NXZHOC53L{GvNkDPxE1?	MVS3JIQ>	MnPGSG1UVw>?	MoPtbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	M1u5V\|I2OTR4OUix
92.1	NUnhSWZyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXOwMlUwOS9{IN88US=>	MkLFO{Bl	M3GzO2ROW09?	MlrhbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	M2XQTlI2OTR4OUix
OCM1	MmH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWLlcGFWOC53L{GvNkDPxE1?	M4jBb\|ch\A>?	MV3EUXNQ	NGLxSWlqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	MnrENlUyPDZ7OEG=
OMM1	MorsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjLNE42NzFxMjFOwG0>	M2LNRlch\A>?	M2\odGROW09?	M{T4PYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	NVHzZZZYOjVzNE[5PFE>
Mel 285	M3Hu[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2DMeFAvPS9zL{Kg{txO	M3f1Z\|ch\A>?	NHLNNGJFVVOR	M{jse4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	MY[yOVE1Pjl6MR?=
Mel 290	NXjyXWg2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2jD[lAvPS9zL{Kg{txO	NEHiPYY4KGR?	M1vyemROW09?	MXnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	M3PpO\|I2OTR4OUix
OCM3	M4TCbWZ2dmO2aX;uJGF{e2G7	M{fJdlAvPS9zIN88US=>	MmjkOFghcA>?	NFrGVIlFVVOR	NFXiWW5l\WO{ZXHz[ZMh[2yxbn;n[Y5q[2m2eTDkc5NmNWSncHXu[IVvfGy7	NX[0W4d6OjVzNE[5PFE>
92.1	MmPVSpVv[3Srb36gRZN{[Xl?	MUKwMlUwOSEQvF2=	NVf0R\|JmPDhiaB?=	Mnm2SG1UVw>?	Mnrr[IVkemWjc3XzJINtd26xZ3XubYNqfHliZH;z[U1l\XCnbnTlcpRtgQ>?	NF3xe2kzPTF2Nkm4NS=>
OCM1	MYrGeY5kfGmxbjDBd5NigQ>?	NH;xUlgxNjVxMTFOwG0>	NWDmSolYPDhiaB?=	NWfROIk5TE2VTx?=	M{fneoRm[3KnYYPld{BkdG:wb3flcolkcXS7IHTvd4Uu\GWyZX7k[Y51dHl?	MWmyOVE1Pjl6MR?=
OMM1	M2\oVGZ2dmO2aX;uJGF{e2G7	M3L4OlAvPS9zIN88US=>	MX[0PEBp	NW\QdnN2TE2VTx?=	NXHaPXNk\GWlcnXhd4V{KGOub37v[4VvcWOrdImg[I9{\S2mZYDlcoRmdnSueR?=	MXSyOVE1Pjl6MR?=
Mel 285	MoPrSpVv[3Srb36gRZN{[Xl?	MXywMlUwOSEQvF2=	MkW3OFghcA>?	NHzkNI9FVVOR	M3:5ToRm[3KnYYPld{BkdG:wb3flcolkcXS7IHTvd4Uu\GWyZX7k[Y51dHl?	M1rtXlI2OTR4OUix
Mel 290	NILtRXJHfW6ldHnvckBCe3OjeR?=	NELtZVYxNjVxMTFOwG0>	NX7qXpM3PDhiaB?=	NHTROJNFVVOR	NGHhblNl\WO{ZXHz[ZMh[2yxbn;n[Y5q[2m2eTDkc5NmNWSncHXu[IVvfGy7	NH;UV4UzPTF2Nkm4NS=>
OCM3	M4mwPWZ2dmO2aX;uJGF{e2G7	NHzk[G4xNjVxMTFOwG0>	MoHXOFghcA>?	MXHEUXNQ	M2fWdIRm[3KnYYPld{Bqdn[jc3nvckBld3OnIHTldIVv\GWwdHz5xsA>	NWLZfIE2OjVzNE[5PFE>
Mel 290	M{f6bWZ2dmO2aX;uJGF{e2G7	NHHOe4wxNjVxMTFOwG0>	Mn;TOFghcA>?	M{XG[GROW09?	NIDuNmJl\WO{ZXHz[ZMhcW64YYPpc44h\G:\|ZTDk[ZBmdmSnboTsfeKh	M3LUOVI2OTR4OUix
OMM1	MVzGeY5kfGmxbjDBd5NigQ>?	NEG1WWYxNjVxMTFOwG0>	M1\y[VQ5KGh?	NEjze5RFVVOR	NID2NFRl\WO{ZXHz[ZMhcW64YYPpc44h\G:\|ZTDk[ZBmdmSnboTsfeKh	M3\2VVI2OTR4OUix
OCM1	MWTD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MonzNE42NzFizszN	MVy1JIQ>	NUHhWWQ2TE2VTx?=	M2jFRoRm[3KnYYPld{Bz[WSrYYTpc44ucW6mdXPl[EBk\WyuII\pZYJqdGm2eTDpcohq[mm2aX;u	MWSyOVE1Pjl6MR?=
92.1	NYW0flc6S2WubDDWbYFjcWyrdImgRZN{[Xl?	MoTDNE42NzFizszN	M3\ybVUh\A>?	MUTEUXNQ	NW\v[ZBs\GWlcnXhd4V{KHKjZHnheIlwdi2rbnT1Z4VlKGOnbHygeoli[mmuaYT5JIlvcGmkaYTpc44>	Mlv5NlUyPDZ7OEG=
OCM1	MlnVSpVv[3Srb36gRZN{[Xl?	M1L5UlAvPS9zIN88US=>	NVfw[3NLPDhiaB?=	NIfQTXhFVVOR	NFPLe4Vk[XW\|ZYOg[4xw[mGuIFTORUBpgXCxbXX0bJlt[XSrb36gZZQhVC1zIILldIVifCCub3Pp	MmXRNlUyPDZ7OEG=
OCM3	M3j3PGZ2dmO2aX;uJGF{e2G7	Ml\mNE42NzFizszN	M2f4blQ5KGh?	NXnTdJhqTE2VTx?=	NE\TVopk[XW\|ZYOg[4xw[mGuIFTORUBpgXCxbXX0bJlt[XSrb36gZZQhVC1zIILldIVifCCub3Pp	NHT6cYgzPTF2Nkm4NS=>
92.1	MYLGeY5kfGmxbjDBd5NigQ>?	Mlu2NE42NzFizszN	MV[0PEBp	NXG1NJozTE2VTx?=	MnjWZ4F2e2W\|IHfsc4JidCCGTlGgbJlxd22ndHj5cIF1cW:wIHH0JGwuOSC{ZYDlZZQhdG:laR?=	NEK2N\|EzPTF2Nkm4NS=>
IMR32	NGnlZ5ZHfW6ldHnvckBCe3OjeR?=	MlP4N{DPxE1?	Mni3O\|IhcA>?	M2rrW2ROW09?	NYT4ZohicW6mdXPld:KheDF7LVnOT\|RlyqCneIDy[ZN{cW:wwrDzbYdvcW[rY3HueIx6	NW\BZmJIOjVzMES4OVA>
IMR5-75	NED6R4JHfW6ldHnvckBCe3OjeR?=	NF\jTpA{KM7:TR?=	NFPOcG44OiCq	NYXDXGc4TE2VTx?=	MoDzbY5lfWOnc9MgdFE6NUmQS{TkxsBmgHC{ZYPzbY9vyqC\|aXfubYZq[2GwdHz5	MlTNNlUyODR6NUC=
Be(2)-C	M1:1UmZ2dmO2aX;uJGF{e2G7	M164eFMh\|ryP	MlLIO\|IhcA>?	M3rabmROW09?	MXXpcoR2[2W\|wrDwNVkuUU6NNHVCpIV5eHKnc4Ppc47DqHOrZ37p[olk[W62bIm=	NGnTPXIzPTFyNEi1NC=>
Bxpc-3	NXvoSnhxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvjOU8yOCEQvF2=	MWmyOE81QC95MjDo		MnjobY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36gc4YhSniyYz2zJINmdGy\|IHnuJJRqdWVvIHHu[EBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XK\|	M3LyVVI2ODZzN{Ox
Bxpc-3	MWPBdI9xfG:\|aYOgRZN{[Xl?	NUPseVVzPS9zMDFOwG0>	NHjG[nMzPC92OD:3NkBp		MkOybY5lfWOnczDhdI9xfG:\|aYOgbY4hfGmvZT2gZY5lKGOxbnPldo51emG2aX;uJI1idm6ncoO=	M32zVVI2ODZzN{Ox
Bxpc-3	MlnNSpVv[3Srb36gRZN{[Xl?	MU[1M\|ExKM7:TR?=	NVfuPGRWOjRxNEivO\|IhcA>?		NXXrWJhN\GWlcnXhd4V{KM7{LXPheIVvcW5iZYjwdoV{e2mxbjDh[pRmeiB{NDDo	NF\O[2szPTB4MUezNS=>
Bxpc-3	MnKySpVv[3Srb36gRZN{[Xl?	MlvzOU8yOCEQvF2=	NXPlbJNYOjRxNEivO\|IhcA>?		MUfk[YNz\WG\|ZYOgZ5lkdGmwREGg[ZhxemW\|c3nvckBifCC2aHWgZ49v[2W{boTyZZRqd25ib3[gNVAh\|ryP	NUjiVVQ2OjVyNkG3N\|E>
Bxpc-3	NViydFNSTnWwY4Tpc44hSXO\|YYm=	MVy1M\|ExKM7:TR?=	NX\LXVJ2OjRxNEivO\|IhcA>?		Mnjm[I94di2{ZXf1cIF1\VNiYz3tfYMhdVKQQTDlfJBz\XO\|aX;uJIlvKHSrbXWtJIFv\CClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYLz	MXeyOVA3OTd\|MR?=
HL-60	MnnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3zOfFEvOCEQvF2=	MYG0PEBp		M{nVTZNq\26rZnnjZY51dHliaX7obYJqfHNiSFytOlAh[2WubDDndo94fGkEoB?=	NEXxTlgzPTB3MUGxPS=>
HL-60	MWjGeY5kfGmxbjDBd5NigQ>?	NWTEbWNrOS5yIN88US=>	Mme3OFghcA>?		NH;oRoVqdmO{ZXHz[ZMheDJzV1HGNU9EUVBzwrDhcoQh[2G\|cHHz[U0{KGW6cILld5Nqd28EoB?=	NYXMZ\|Z4OjVyNUGxNVk>
HL-60	Mki1SpVv[3Srb36gRZN{[Xl?	NXmwTXN6OS5yIN88US=>	MWS0PEBp		NHrKOZRl\WO{ZXHz[ZMhSmOuLYjMJIV5eHKnc4Ppc47DqHOrZ37p[olk[W62bIm=	MUOyOVA2OTFzOR?=
HuTu-80	NF36ZXlHfW6ldHnvckBCe3OjeR?=	M4TaXlEwPS9zMDFOwG0>	Mn\GOFgwPzJiaB?=		NXvKdIxucW6lcnXhd4V{KHSqZTDlfJBz\XO\|aX;uJI9nKGi3bXHuJG5RSzGOMTDtVm5CKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NETUfGQzPDlyNEC2Ni=>
Caco2	NH;YfJhHfW6ldHnvckBCe3OjeR?=	NE\UN3YyOCEQvF2=	NGLQOJo1QCCq		NWPwR3lxcW6lcnXhd4V{KE6SQ{HMNUBmgHC{ZYPzbY9v	NILafZEzPDlyNEC2Ni=>
HepG2	MlXQSpVv[3Srb36gRZN{[Xl?	MknHNE0zPSEQvF2=	MnPhNlQhcA>?		M4XU[4Rm[3KnYYPld{B{fWK2aXzpd4lvN2uneHnuJJR6eGViOTCoVGNUUzlrIIDyc5RmcW5ibHX2[Yx{KGSxc3Wg[IVx\W6mZX70cJk>	NFv1eGszPDh3NU[0Oi=>
HepG2	MmXNSpVv[3Srb36gRZN{[Xl?	Mke3NE0zPSEQvF2=	NFLQTGgzPCCq		M4D5RYlv[3KnYYPld{Btd3diZHXud4l1gSCuaYDvdJJwfGWrbjDy[YNmeHSxcjCoUGRNWiliZ3Xu[UBmgHC{ZYPzbY9vyqB?	MkLMNlQ5PTV4NE[=
HepG2	NUC1NYY1TnWwY4Tpc44hSXO\|YYm=	NXm4XJRrOTBizsztxsA>	MV[wMVI1KGh?		NYTiNFRm\GWlcnXhd4V{yqCSQ2PLPeKh[W6mwrDIUWdEWsLiZYjwdoV{e2mxbjDhcoQhcW6lcnXhd4V{KEyGTGKg[ZhxemW\|c3nvckBi\nSncjC2JIg>	M4nYXFI1QDV3NkS2
HepG2	NVXkSodJTnWwY4Tpc44hSXO\|YYm=	NUe3VpBWOTBizszt	M2LvO\|I1KGh?		MUTwdo9ud3SnczDjfZRwe2:uaXOgcoV2fHKjbDDsbZBq\CCjY3P1cZVt[XSrb36gbY5l\XCnbnTlcpRtgSCxZjDlfI9o\W6xdYOgcIlxd3C{b4TlbY5{	NGXTVXIzPDh3NU[0Oi=>
HepG2	MXzGeY5kfGmxbjDBd5NigQ>?	Mn\KNVAh\|ryv	M3r6O\|I1KGh?		MnjodJJmfmWwdIOgV3JGSlBicILvZ4V{e2mwZx?=	MXqyOFg2PTZ2Nh?=
HC45	M4\xPWZ2dmO2aX;uJGF{e2G7	MVK1xtVOyqB?	MUG0JIQ>		MUjy[YR2[2W\|IITo[UBu\XSqeXzheIlwdiCuZY\lcJMhd2ZiV1nGNUwhWDF4LDDDXGNNOTRuIF7LXFLjiJN\|LDDDSGgyNCCOQV3BNUwh[W6mIFPUUm5DOQ>?	M3TxXlI1PzZ{OEC5
CNDT2	NVXMXoVUTnWwY4Tpc44hSXO\|YYm=	NF\V[I42yrWPwrC=	MkPZOEBl		NHTSR3Jz\WS3Y3XzJJRp\SCvZYTofYxifGmxbjDs[ZZmdHNib3[gW2lHOSxiUEG2MEBEYEOOMUSsJG5MYDMkgKOzMEBETEhzLDDMRW1COSxiYX7kJGNVVk6EMR?=	NXewcXNCOjR5NkK4NFk>
CNDT2	NEDU[WtHfW6ldHnvckBCe3OjeR?=	MWK1xtVOyqB?	NF;mTVQ1KGR?		NHnrWlZqdmO{ZXHz[ZMh\2WwZTDlfJBz\XO\|aX;uJI9nyqCZSV[xMEBROTZuIFPETFEtyqCOQV3BNUzDqGGwZNMgR3RPVkJz	MYCyOFc3OjhyOR?=
T-cells	NVz1UpFZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml\xOU8zOCEQvF2=	NITrbXMxNTR6IHi=		NGr0[3hqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	MnTDNlQ4PTd{OEO=
CD3+ T-cells	NWWy[XZiTnWwY4Tpc44hSXO\|YYm=	M3vxeVUwOjBizszN	Ml7vOFghcA>?		M{SxNJVxemWpdXzheIV{KHBzNTDlfJBz\XO\|aX;u	NV3XcGgxOjR5NUeyPFM>
CD4+ T-cells	M4LJN2Z2dmO2aX;uJGF{e2G7	MUG1M\|IxKM7:TR?=	NFjXRZE1QCCq		MVz1dJJm\3WuYYTld{BxOTViZYjwdoV{e2mxbh?=	M4O5eFI1PzV5Mkiz
CD8+ T-cells	MXfGeY5kfGmxbjDBd5NigQ>?	MV21M\|IxKM7:TR?=	M3j6cFQ5KGh?		MVX1dJJm\3WuYYTld{BxOTViZYjwdoV{e2mxbh?=	NWPEWHViOjR5NUeyPFM>
CD3+ T-cells	NGnXT5BHfW6ldHnvckBCe3OjeR?=	NWPxSohXPS9{MDFOwG0>	NVT5N3U{PDhiaB?=		MlvOeZBz\We3bHH0[ZMhfGinIHX4dJJme3Orb36gc4YhTk:[UEO=	NYLM[YhLOjR5NUeyPFM>
CD4+ T-cells	NEnBdFNHfW6ldHnvckBCe3OjeR?=	NVrhUFA2PS9{MDFOwG0>	MnvvOFghcA>?		MofWeZBz\We3bHH0[ZMhfGinIHX4dJJme3Orb36gc4YhTk:[UEO=	MmPqNlQ4PTd{OEO=
CD4+ T-cells	M1\oTmZ2dmO2aX;uJGF{e2G7	Mn3JOU8zOCEQvF2=	NVLyU2lrPDhiaB?=		MlzsdoVlfWOnczDURmVVOcLibWLORUBmgHC{ZYPzbY9v	NFTFXmUzPDd3N{K4Ny=>
CD4+ T-cells	MXvGeY5kfGmxbjDBd5NigQ>?	MUm1M\|IxKM7:TR?=	MVi0PEBp		MWH1dJJm\3WuYYTld{B1cGViZYjwdoV{e2mxbjDv[uKhWk:UzsP0xsA>	MkXhNlQ4PTd{OEO=
CD4+ T-cells	MmX0SpVv[3Srb36gRZN{[Xl?	MomyOU8zOCEQvF2=	NUPIXVcyPDhiaB?=		MorjbY5pcWKrdIOgcYVud3K7IGStZ4VtdHN?	NFL5bmYzPDd3N{K4Ny=>
CD8+ T-cells	MWTGeY5kfGmxbjDBd5NigQ>?	MnrZOU8zOCEQvF2=	M4TjWFQ5KGh?		MortbY5pcWKrdIOgcYVud3K7IGStZ4VtdHN?	NF7NR2QzPDd3N{K4Ny=>
CD3+ T-cells	NVKzZmg4TnWwY4Tpc44hSXO\|YYm=	NGHjTY82KM7:TR?=	MXS0PEBp		MYDy[YR2[2W\|IHzvcocufGW{bTDt[Y1wenliY3XscEBxcGWwb4T5dIU>	NWrKNYY{OjR5NUeyPFM>
U937	NXPwd241SXCxcITvd4l{KEG\|c3H5	MoHUNVAh\|ryP	M4LJNVczKGh?		MmH2bY5lfWOnczDhdI9xfG:\|aYOgd4lodmmoaXPhcpRtgQ>?	NH3jNZAzPDZ6MEi2OS=>
HL-60	NILZUXVCeG:ydH;zbZMhSXO\|YYm=	MnGzNVAh\|ryP	MXi3NkBp		M3GzXYlv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHl?	NGXWNGgzPDZ6MEi2OS=>
MCF7	NGn2NYVHfW6ldHnvckBCe3OjeR?=	M3T2XVUh\|ryP	MkHrOFghcMLi		MX\kbZNxdGG7czDz[Yxm[3SrdnWgeI95cWOrdImgeI94[XKmIIP1d5BmdmSnZDDNR2YuPyClZXzsdy=>	MWGyOFY{OzN3MB?=
MCF7	NF\HUZNHfW6ldHnvckBCe3OjeR?=	NULSb2V6OTBizszN	MkLPNlQhcMLi		Mnf0bY5lfWOnczD0bIUh[2ynYY\h[4Uhd2ZiY3HzdIF{\SB5IHHu[EBRSVKSwrC=	NX3lXWkzOjR4M{OzOVA>
MCF7	NUHUVo4zTnWwY4Tpc44hSXO\|YYm=	NHv3NoEx6oDVMD61JO69VcLi	NXLTNlh2PyCm		MXzpcohq[mm2czD0bIUh\3Kxd4ToJG1ETi15IIT1cY9ze3CqZYLld{BqdiC\|dYPw[Y5{cW:wIHP1cJR2emW\|wrC=	NUPPN\|RbOjR4M{OzOVA>
MCF7	M2PMRWZ2dmO2aX;uJGF{e2G7	M4LkOlAvPSEQvF5CpC=>	MU[xOEBl		NU\aPJBqemWmdXPld{B1cGVic3n6[UBw\iCPQ1[tO{Bkd2yxbnnld{BmdWKnZHTl[EBqdiC\|b3\0JIFo[XJ?	NE\v[Y0zPDZ\|M{O1NC=>
MCF7	MmTmSpVv[3Srb36gRZN{[Xl?	NIrkUncxNjB34pETNlAh\|ryP	NEnjcmwyKGR?		M1\nNJJm\HWlZYOgeIhmKGOub37hcEB{fXK4aY\hcEBw\iCPQ1[tO{Bk\WyuczDpckBud26xbHH5[ZIh[3WudIXy[ZM>	MnO5NlQ3OzN\|NUC=
T47D	MmXOSpVv[3Srb36gRZN{[Xl?	NWTCS2Q4OC53IN88US=>	NI\kXpo1KGR?		MkjKbY5pcWKrdIOgeJVud3K\|cHjldoUh\m:{bXH0bY9v	MWSyOFY{OzN3MB?=
MCF7	NVHZWnBtTnWwY4Tpc44hSXO\|YYm=	Mon5NE426oDVMUCg{txO	MYK0PEBpyqB?		NYLFSFdYcW6qaXLpeJMhfGinIHfhdEBkdG:\|dYLlJIlvKHSqZTD3c5Vv\CCqZXHsbY5oKGG\|c3H5	M2rlNVI1PjN\|M{Ww
MCF7	NIjLOIlHfW6ldHnvckBCe3OjeR?=	MXSwM\|ExKM7:TR?=	Mlr2NlQhcA>?		NUn5WGhQcW6qaXLpeJMhfGinIHHjeIl3cXS7IH;mJG1OWDl?	MVuyOFY{OzN3MB?=
MDA-MB-231	NIXEXYRHfW6ldHnvckBCe3OjeR?=	MlvuNE426oDVMUCg{txO	M33FZVM3KGh?		NXviWm9KcW6qaXLpeJMhfGinIH3p[5JifGmxbh?=	NI\qeFMzPDZ\|M{O1NC=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	DNMT1 ; PubMed: 28210112 Lung Cancer (Auckl) AZA and DAC cause DNMT1 depletion in NSCLC cell lines. A549 and H1299 cells were treated with AZA or DAC (0–5 µM) for 20 hours and DNMT1 protein was detected by Western blotting of cell extracts. Alpha-tubulin was used as a loading control. c-PARP / p-H2AX / H2AX; PubMed: 28210112 Lung Cancer (Auckl) AZA, but not DAC, induces markers of DNA damage and apoptosis in NSCLC cell lines. A549 and H1299 cells were treated with AZA or DAC (0–10 µM) for 48 hours and Western blotting of cell extracts was used to detect DNMT1, cleaved-PARP, phospho-histone-H2AX(䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖Ѐ瑖堘	28210112
Immunofluorescence	HMGB1 ; PubMed: 29097772 Sci Rep U2OS cells stably expressing a GFP-HMGB1 fusion were maintained in control conditions (Ctrl), suberoylanilide hydroxamic acid (SAHA), azacitidine (AZA) for 24 h or 48 h, followed by assessment of cytoplasmic GFP-HMGB1 fluorescence intensity (A,B) or endog䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ෆĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ⟸෕䐺痖暼瘿⟸෕ᾰƌ ⟸෕Ð㺣痖⟸෕𢡄⟼෕䀷痗⟼෕౴⟼෕㵶痗⟼෕뺖᎒泌Itemｾ᎒	29097772
Growth inhibition assay	Cell viability ; PubMed: 28210112 Lung Cancer (Auckl) AZA and DAC differentially affect cell viability in a panel of NSCLC cell lines. Viability of A549, H460, and H1299 cells was assessed after 72 hours of treatment with AZA or DAC (0–25 µM). Error bars represent the standard error of mean of 3 independent 䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖	28210112

In vivo

Azacitidine inhibits polynucleotide synthesis in leukemic BDF₁ mice. ^[3] Azacitidine (3 mg/kg, i.p.) increases the mean survival time in leukemic BDF1 mice inoculated with Ll210 ascites tumor cells. Azacitidine markedly suppresses all enzymes activity in the polyamine-biosynthetic pathway, including ornithine decarboxylase activity. putrescine-dependent S-adenosyl-L-methionine decarboxylase activity, and spermidine-dependent S-adenosyl-L-methionine decarboxylase activity. Azacitidine also inhibits the accumulations of polyamines in leukemic mice. ^[4]

Protocol

Cell Research:^[3]	- Collapse Cell lines: Leukemia L1210 cell Concentrations: 0.15 μg/mL Incubation Time: 3 days Method: 5 mL of L1210 cells (5 × 10³ cells/mL) are incubated with Azacitidine at 37 ℃ for 3 days. Cell number is determined twice a day for 3 days by means of a Model A Coulter counter. (Only for Reference)
Animal Research:^[4]	- Collapse Animal Models: BDF1 mice bearing lymphoid leukemia L1210 Dosages: 3 mg/kg Administration: Daily i.p. injection (Only for Reference)

References

[4] Heby O, et al. Cancer Res. 1973, 33(1), 159-165.

- Collapse

Solubility (25°C)

In vitro	DMSO	48 mg/mL warmed (196.56 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Azacitidine (5-Azacytidine) SDF

Molecular Weight	244.2
Formula	C₈H₁₂N₄O₅
CAS No.	320-67-2
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	5-AzaC,Ladakamycin, AZA,5-Aza
Smiles	C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-09-01)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04172844	Recruiting	Drug: Azacitidine\|Drug: Venetoclax\|Drug: Pevonedistat	Acute Myelogenous Leukemia	Ehab L Atallah\|Medical College of Wisconsin	January 13 2020	Phase 1
NCT04214860	Recruiting	Drug: APR-246\|Drug: Venetoclax\|Drug: Azacitidine	Myeloid Malignancy	Aprea Therapeutics	December 13 2019	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Is the vehicle (30% Propylene glycol, 5% Tween 80, 65% D5W) for Azacitidine (Catalog No.S1782) safe for subcutaneous dosing?
Answer:
S1782 in 30% Propylene glycol+5% Tween 80+65% D5W at 30mg/ml is a suspension. If you are going to administrate this compound for oral gavage, it is fine. But if you administrate the drug via injection, you need a clear solution and S1782 can be dissolved in 5% DMSO+30% PEG 300+ddH2O at 10mg/ml clearly.

Choose Your Country or Region

By Signaling Pathways

By product type

Azacitidine (5-Azacytidine)